Browse the evidence

GLP-1RAs promote weight loss and improve metabolic health.

GLP-1RAs can be utilized to aid in weight management and metabolic health improvement.

Obesity is a major contributor to type 2 diabetes, necessitating medication management for both conditions.

Addressing obesity is crucial in managing type 2 diabetes, and medication may be necessary.

Exenatide combined with Metformin significantly reduced insulin resistance (HOMA-IR) by a mean difference of -0.9 (p < 0.001).

Practitioners may consider the combination of Exenatide and Metformin as an effective treatment for improving insulin resistance in women with PCOS.

Exenatide combined with Metformin reduced body mass index (BMI) by a mean difference of -0.4 (p = 0.03).

The combination therapy may assist in weight management for women with PCOS.

All secondary cardiometabolic outcomes improved significantly throughout the study.

Practitioners can consider compounded GLP-1 ± GIP agonists as effective for improving various cardiometabolic risk factors.

Intensive lifestyle modification and medications that improve insulin resistance are key strategies for preventing type 2 diabetes (T2D).

Practitioners should focus on lifestyle changes and medications to prevent T2D.

Meal replacements (MRs) lead to a significant reduction in fasting blood sugar (FBS) by 3.10 mg/dL.

Incorporating meal replacements can effectively lower fasting blood sugar levels.

Chronic data generally indicate that supersets and traditional resistance training lead to similar adaptations for endurance, hypertrophy, power, and strength.

Both training modalities can be used interchangeably for long-term adaptations.

Training-induced changes in leg lean body mass and leg press 1RM increased after training with no differences between rBLG and whey groups.

Both rBLG and whey can effectively support muscle gains from resistance training.

Semaglutide add-on to metformin significantly decreases the Visceral Adiposity Index (VAI) in type 2 diabetic patients, with the greatest reduction in the obesity group (-0.70).

Incorporating semaglutide with metformin may enhance fat loss in patients with type 2 diabetes, especially those with obesity.

Weight loss is associated with improvement in cardiovascular risk, menstrual cycles, ovulation, and pregnancy rate in women with obesity and PCOS.

Weight loss should be prioritized in treatment plans for women with obesity and PCOS to improve health outcomes.

Tirzepatide yields greater weight loss and broad metabolic benefits.

Clinicians may prefer tirzepatide for patients focused on weight loss and metabolic improvements.

Lean mass was largely preserved with no declines in resting metabolic rate (RMR) in the BHB group.

BHB supplementation may help maintain lean mass during caloric restriction.

Achieving ≥ 5% total weight loss (TWL) is associated with a higher risk ratio (RR) of type 2 diabetes remission (RR = 7.88).

Practitioners should encourage patients to aim for at least 5% weight loss to improve diabetes remission rates.

Achieving ≥ 5% TWL is associated with a higher RR of hypertension remission (RR = 2.23).

Encouraging weight loss of at least 5% may help patients achieve better blood pressure control.

Achieving ≥ 5% TWL leads to significant mean differences in metabolic risk factors including HbA1c, fasting plasma glucose, and blood pressure.

Weight loss of at least 5% can lead to significant improvements in key metabolic health indicators.

Intermittent fasting has cardiometabolic effects in persons with prediabetes and type 2 diabetes.

Healthcare providers may consider intermittent fasting as a potential dietary intervention for patients with prediabetes and type 2 diabetes.

Semaglutide consistently produces substantial reductions in body weight and visceral fat, accompanied by improvements in blood pressure, glycemic control, inflammatory markers, and hepatic steatosis.

Practitioners can expect significant improvements in metabolic health markers with semaglutide use.

FDA-approved medications such as orlistat, phentermine/topiramate, bupropion/naltrexone, and liraglutide have significantly improved weight-loss outcomes.

Practitioners can consider these medications as effective options for weight management.

Semaglutide and tirzepatide achieve weight-loss outcomes comparable to bariatric surgery.

These medications may be considered as alternatives to surgical weight loss options.

Participants with greater weight reduction showed significantly greater improvements in cardiometabolic markers.

Encouraging weight loss may enhance cardiometabolic health in individuals.

Metabolic syndrome prevalence dropped from 21.6% at baseline to 0% by week 52.

Achieving a normal BMI may eliminate metabolic syndrome risk in individuals.

Periodic fasting (PF) improves albuminuria in patients with type 2 diabetes (T2D) and diabetic nephropathy (DN).

Implementing periodic fasting may be beneficial for managing albuminuria in patients with T2D.

Pharmacotherapy is highly effective in reducing body weight and improving metabolic parameters.

Pharmacotherapy should be considered as a key component in obesity treatment plans.